VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Bordetella pertussis D420
Phase 1
Biologic
D
Dalhousie University
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Pertussis
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Pertussis
Phase 1
Completed
Clinical
Trials by Indication
[1]
Pertussis
1 trial
Open-label, Phase 1, Dose-escalation Clinical Trial to Establish a Controlled Human Infection Model by Determining the Optimal and Safe Bordetella Pertussis Dose That Induces Mild Symptomatic Infection and Colonization in Healthy Adults
Completed
·
D
Dalhousie University
·
Phase 1
·
NCT05136599
·
79 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for Bordetella pertussis D420. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Bordetella pertussis D420 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Bordetella pertussis D420. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Dalhousie University company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Biologic
[2]
Highest Phase
Phase 1
[1]
Company
D
Dalhousie University
Related News